ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint. Major Capital Structure Optimization Exousia Pro has successfully completed the cancellation of derivative securities convertible into 47 million shares of Common Stock. This substanti ...

ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint. Major Capital Structure Optimization Exousia Pro has successfully completed the cancellation of derivative securities convertible into 47 million shares of Common Stock. This substanti ...